ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer

  • Post author:
  • Post category:Newsroom

ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.

Menu